Labiotech.eu

News and Trends 2 Nov 2016

Antibody Therapies are here to Revolutionize Dermatology

Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […]

November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

biorefinery review europe biomass bioeconomy

In Depth 2 Nov 2016

Green Waste is Biotech’s New Black Gold: A Review of Biorefineries

Replacing petroleum-based products with biobased equivalents is the Holy Grail of the bioeconomy. What are biorefineries doing and how can Biotech help? ‘Biorefinery’ is a buzzword for a cool technological space that draws from GreenTech, Industrial Biotech and SynBio. The core concept behind it is relatively simple: these plants mimic the traditional petroleum refinery, but […]

November 2, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 2 Nov 2016

NHS adopts Next-Gen Sequencing to Test for Birth Defects

Despite a lawsuit from Illumina, Premaitha forged ahead with its NGS-based non-invasive prenatal test; the NHS just adopted it as a standard screen. With its seemingly infinite applications, next-generation sequencing (NGS) is a hot area, especially for diagnostics biotechs. A number have been founded in recent years to develop prenatal tests for birth defects, and […]

November 2, 2016 - 3 minutesmins - By Evelyn Warner

Screenshot 2016 11 01 at 3.27.32 PM e1478010517232

News and Trends 1 Nov 2016

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […]

November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Nov 2016

This Technology could Open Up a new 4th Generation of Therapeutic Antibodies

From everyday immunostaining to billion-euro therapies, antibodies have become essential in Biotech. Selecting the right antibodies that are as close to human as possible minimizes risks and can be the key to success, especially in medical applications. What goes into making the best therapeutic antibodies? To answer this question, we sat down with BIOTEM, an experienced provider of custom […]

November 1, 2016 - 5 minutesmins - By External Contributor

News and Trends 1 Nov 2016

The Toilet has been Reinvented: Now it is Waterless!

About 1,400 children under 5 die of sanitation-related illnesses daily. The Cranfield Water Science Institute and the Gates Foundation may have a solution: a waterless toilet. Lack of access to clean water and proper sanitation is the main issue in third-world and developing countries, causing health issues and drinking water contamination. Over 2.4 billion people […]

November 1, 2016 - 5 minutesmins - By Joachim Eeckhout

News and Trends 31 Oct 2016

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

Ganymed Pharmaceuticals is the protagonist of Germany’s biggest biotech deal ever; Astellas Pharma has offered up to €1.3B to get hold of Ganymed’s first-in-class cancer antibody technology. Ganymed Pharmaceuticals develops first-in-class antibody therapies for cancer. Its technology seems to be so promising that the Japanese Astellas Pharma has decided to acquire it in what will be the […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Oct 2016

This might be the First 3-in-1 Therapy for Highly Metastatic Cancer

Amcure’s candidate for highly metastatic epithelial cancers is about to start clinical trials. The compound can shut down three oncological pathways simultaneously through a single molecular target. Amcure is a spin-off from the Karlsruhe Institute of Technology in Germany, established in 2012. The company develops treatments for highly metastatic forms of cancer using peptide-based compounds targeting angiogenesis. It […]

October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Sanofi regeneron rheumatoid arthritis salurimab

News and Trends 31 Oct 2016

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US FDA and EMA approval, the results from the latest study were presented at the American College of Rheumatology (ACR) annual meeting in San Francisco. Should Sarilumab be approved, this immunotherapy will be used to treat […]

October 31, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 31 Oct 2016

Meet the Jellyfish Medtech seeking to disrupt the Collagen Market

Jellyfish are a source of collagen: this is the idea behind the winner of Boost Cymru, a competition of the Life Sciences Hub Wales. We had a chat with Andrew Mearns-Spragg, CEO of Jellagen, about this promising startup. The jellyfish already has a place in Biotech’s hall of fame as the source of the gene for […]

October 31, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 29 Oct 2016

Aliens in the Cornfield: The Borg Are Taking over Nebraska

The assimilation of the human race has begun! A Star Trek nightmare is coming true, as biohackers recruit piercing artists to build human-based Borg. Similar to the Borg’s obsession with perfecting biological life through machinery, biohackers are driven to make human life easier with technological implants. The first trials have already begun, as some biohackers have […]

October 29, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 28 Oct 2016

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […]

October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibody Therapies are here to Revolutionize Dermatology

Green Waste is Biotech’s New Black Gold: A Review of Biorefineries

NHS adopts Next-Gen Sequencing to Test for Birth Defects

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin

This Technology could Open Up a new 4th Generation of Therapeutic Antibodies

The Toilet has been Reinvented: Now it is Waterless!

Shooting for the Moon: German Biotech Acquired for a Record €1.3B

This might be the First 3-in-1 Therapy for Highly Metastatic Cancer

UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug

Meet the Jellyfish Medtech seeking to disrupt the Collagen Market

Aliens in the Cornfield: The Borg Are Taking over Nebraska

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!